What is Viking Therapeutics Inc's earnings per share (EPS)?

Viking Therapeutics Inc (VKTX) reported diluted earnings per share of -$3.19 for fiscal year 2025. This represents a -215.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Viking Therapeutics Inc Financials

VKTX

FY2025 annual

Revenue $0 YoY not available

Net Income -$359.6M -227.1% YoY

EPS (Diluted) -$3.19 -215.8% YoY

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Viking Therapeutics Inc (VKTX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VKTX FY2025 2026-08-26

Development-stage cash consumption is intensifying as R&D expands while the balance sheet’s asset cushion shrinks.

In FY2025, the cash-conversion gap mattered: net loss was -$359.6M while operating cash flow was -$278.7M, so accounting loss exceeded cash outflow rather than translating dollar-for-dollar into it. R&D reached $345.0M, larger than the operating cash outflow, which is consistent with development spending and noncash accounting effects shaping the gap.

The balance sheet became less forgiving: total assets fell from $908.3M in FY2024 to $715.7M in FY2025. Liabilities rose from $28.0M to $76.7M, while the still-high current ratio and low debt-to-equity indicate reduced financial cushion rather than a debt-heavy structure.

R&D rose from $101.6M in FY2024 to $345.0M in FY2025, making scientific investment the dominant operating commitment. Operating losses widened sharply, and shares outstanding also increased, indicating that the larger development program has not yet been absorbed by operating earnings and has coincided with additional equity issuance.

Financial Health Signals

Financial health score not available

Viking Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

26.96

Viking Therapeutics Inc scores 26.96, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.8B) relative to total liabilities ($76.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Viking Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Viking Therapeutics Inc reported a net loss of $359.6M while operations used $278.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Viking Therapeutics Inc generated $0 in revenue in fiscal year 2025.

Net Income

-$359.6M

YoY-227.1%

Viking Therapeutics Inc reported -$359.6M in net income in fiscal year 2025. This represents a decrease of 227.1% from the prior year.

EPS (Diluted)

-$3.19

YoY-215.8%

Viking Therapeutics Inc earned -$3.19 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 215.8% from the prior year.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$165.8M

YoY+521.6%

5Y CAGR+41.6%

10Y CAGR+71.2%

Viking Therapeutics Inc held $165.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

116M

YoY+2.9%

5Y CAGR+9.3%

Viking Therapeutics Inc had 116M shares outstanding in fiscal year 2025. This represents an increase of 2.9% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-56.3%

YoY-43.8pp

5Y CAGR-40.1pp

10Y CAGR+212.0pp

Viking Therapeutics Inc's ROE was -56.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 43.8 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$345.0M

YoY+239.4%

5Y CAGR+61.0%

10Y CAGR+47.7%

Viking Therapeutics Inc invested $345.0M in research and development in fiscal year 2025. This represents an increase of 239.4% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

VKTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

VKTX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expenses	N/A	$345.0M+239.4%	$101.6M+59.3%	$63.8M+17.6%	$54.2M+20.6%	$45.0M+40.9%	$31.9M+35.5%	$23.6M+23.7%	$19.0M+38.6%	$13.7M+52.7%	$9.0M+29.2%	$7.0M	N/A
SG&A Expenses	N/A	$48.4M-1.8%	$49.3M+33.1%	$37.0M+129.6%	$16.1M+50.6%	$10.7M-0.3%	$10.7M+17.6%	$9.1M+28.2%	$7.1M+33.6%	$5.3M+9.9%	$4.8M-3.6%	$5.0M+304.0%	$1.2M
Operating Income	N/A	-$393.3M-160.6%	-$150.9M-49.7%	-$100.8M-43.3%	-$70.4M-26.4%	-$55.7M-30.5%	-$42.7M-30.5%	-$32.7M-24.9%	-$26.2M-37.2%	-$19.1M-37.7%	-$13.8M-15.4%	-$12.0M	N/A
Income Tax	N/A	$1K0.0%	$1K0.0%	$1K0.0%	$1K-50.0%	$2K	$0	$0	$0	$0	$0	N/A	N/A
Net Income	N/A	-$359.6M-227.1%	-$110.0M-28.0%	-$85.9M-24.7%	-$68.9M-25.2%	-$55.0M-39.2%	-$39.5M-53.2%	-$25.8M-16.8%	-$22.1M-7.2%	-$20.6M-39.7%	-$14.7M+37.1%	-$23.4M	N/A
EPS (Diluted)	-$4.67	-$3.19-215.8%	-$1.01-11.0%	-$0.91-1.1%	-$0.90-26.8%	-$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0
R&D Expenses	$115.8M-22.9%	$150.2M	N/A	$90.0M+49.5%	$60.2M+45.3%	$41.4M	N/A	$22.8M
SG&A Expenses	$16.8M+20.5%	$14.0M	N/A	$8.6M-40.3%	$14.4M+2.4%	$14.1M	N/A	$13.8M
Operating Income	-$132.6M+19.2%	-$164.1M	N/A	-$98.6M-32.2%	-$74.6M-34.4%	-$55.5M	N/A	-$36.6M
Net Income	-$128.0M+19.1%	-$158.3M	N/A	-$90.8M-38.5%	-$65.6M-43.7%	-$45.6M	N/A	-$24.9M
EPS (Diluted)	-$1.10+19.7%	-$1.37+1.4%	-$1.39-71.6%	-$0.81-39.7%	-$0.58-41.5%	-$0.41-28.1%	-$0.32-45.5%	-$0.22

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

VKTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

VKTX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Total Assets	$715.7M-21.2%	$908.3M+146.5%	$368.5M+118.7%	$168.5M-20.0%	$210.7M-17.9%	$256.5M-9.8%	$284.3M-6.0%	$302.3M+1266.6%	$22.1M+52.2%	$14.5M-5.9%	$15.4M+407.3%	$3.0M
Current Assets	$715.6M-21.1%	$907.2M+147.0%	$367.2M+119.8%	$167.0M-20.7%	$210.5M-17.8%	$256.1M-9.7%	$283.5M-6.2%	$302.1M+1282.7%	$21.9M+56.4%	$14.0M-8.1%	$15.2M+1864.8%	$774K
Cash & Equivalents	$165.8M+521.6%	$26.7M-51.9%	$55.5M+51.6%	$36.6M+38.9%	$26.4M-9.4%	$29.1M+247.6%	$8.4M-66.2%	$24.8M+175.7%	$9.0M+192.2%	$3.1M+300.2%	$769K+1.7%	$756K
Total Liabilities	$76.7M+173.4%	$28.0M+39.7%	$20.1M-13.5%	$23.2M+164.4%	$8.8M-27.8%	$12.2M+70.4%	$7.1M+56.4%	$4.6M-47.3%	$8.7M+33.3%	$6.5M-3.3%	$6.7M-73.3%	$25.2M
Current Liabilities	$76.7M+179.7%	$27.4M+43.3%	$19.1M-12.8%	$21.9M+150.0%	$8.8M-27.6%	$12.1M+79.0%	$6.8M+48.9%	$4.5M-47.4%	$8.7M+33.7%	$6.5M+227.6%	$2.0M-91.2%	$22.5M
Total Equity	$639.1M-27.4%	$880.3M+152.6%	$348.4M+139.8%	$145.3M-28.0%	$201.9M-17.4%	$244.3M-11.8%	$277.1M-6.9%	$297.8M+2111.5%	$13.5M+67.4%	$8.0M-7.8%	$8.7M+139.4%	-$22.1M
Retained Earnings	-$847.5M-73.7%	-$487.9M-29.1%	-$377.9M-29.4%	-$292.0M-30.9%	-$223.2M-32.7%	-$168.2M-30.7%	-$128.7M-25.0%	-$102.9M-27.3%	-$80.9M-34.1%	-$60.3M-32.3%	-$45.5M-105.7%	-$22.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$521.9M-14.2%	$608.2M-15.0%	$715.7M-3.2%	$739.4M-10.7%	$827.9M-4.5%	$867.0M-4.5%	$908.3M-3.2%	$937.9M
Current Assets	$517.6M-14.9%	$608.2M-15.0%	$715.6M-3.1%	$738.7M-10.7%	$827.0M-4.5%	$866.0M-4.5%	$907.2M-3.1%	$936.6M
Cash & Equivalents	$125.8M+6.5%	$118.1M-28.8%	$165.8M+65.2%	$100.4M+196.3%	$33.9M-10.7%	$37.9M+42.2%	$26.7M-47.0%	$50.3M
Total Liabilities	$113.6M+6.8%	$106.3M+38.7%	$76.7M+190.6%	$26.4M-18.5%	$32.4M+61.3%	$20.1M-28.4%	$28.0M+6.1%	$26.4M
Current Liabilities	$109.7M+3.1%	$106.3M+38.7%	$76.7M+194.1%	$26.1M-18.5%	$32.0M+63.4%	$19.6M-28.6%	$27.4M+6.7%	$25.7M
Total Equity	$408.3M-18.6%	$501.9M-21.5%	$639.1M-10.4%	$713.0M-10.4%	$795.5M-6.1%	$846.9M-3.8%	$880.3M-3.4%	$911.4M
Retained Earnings	-$1.1B-12.7%	-$1.0B-18.7%	-$847.5M-22.9%	-$689.9M-15.2%	-$599.1M-12.3%	-$533.5M-9.4%	-$487.9M-7.8%	-$452.5M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

VKTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

VKTX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$418.4M	-$278.7M-217.4%	-$87.8M-19.6%	-$73.4M-51.6%	-$48.4M-1.7%	-$47.6M-118.5%	-$21.8M+12.0%	-$24.8M-32.0%	-$18.8M-27.1%	-$14.8M-33.3%	-$11.1M-26.8%	-$8.7M-448.7%	-$1.6M
Investing Cash Flow	$399.3M	$341.4M+161.7%	-$553.4M-209.0%	-$179.1M-427.1%	$54.8M+44.2%	$38.0M-8.7%	$41.6M+457.0%	$7.5M+102.8%	-$265.7M-15260.1%	-$1.7M	N/A	N/A	N/A
Financing Cash Flow	$111.2M	$76.4M-87.5%	$612.5M+125.7%	$271.4M+6418.8%	$4.2M-39.5%	$6.9M+624.2%	$950K+7.1%	$887K-99.7%	$300.3M+1240.5%	$22.4M	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$6.8M	N/A	N/A	N/A	N/A	N/A	$229+502.6%	$38+1800.0%	$2

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$125.2M-9.8%	-$114.0M-33.6%	-$85.3M+9.3%	-$94.0M-99.7%	-$47.1M+10.1%	-$52.3M-67.8%	-$31.2M-42.0%	-$22.0M
Investing Cash Flow	$109.4M+101.9%	$54.2M-28.3%	$75.6M-52.7%	$160.0M+276.5%	$42.5M-32.8%	$63.2M+860.6%	$6.6M-74.6%	$25.9M
Financing Cash Flow	$23.6M+95.3%	$12.1M-83.9%	$75.1M+15546.5%	$480K-5.3%	$507K+45.3%	$349K-65.1%	$1.0M-60.3%	$2.5M

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

VKTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

VKTX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Return on Equity	-56.3%-43.8pp	-12.5%+12.2pp	-24.6%+22.7pp	-47.4%-20.2pp	-27.2%-11.1pp	-16.2%-6.9pp	-9.3%-1.9pp	-7.4%+145.4pp	-152.8%+30.3pp	-183.2%+85.1pp	-268.2%	N/A
Return on Assets	-50.2%-38.1pp	-12.1%+11.2pp	-23.3%+17.6pp	-40.9%-14.8pp	-26.1%-10.7pp	-15.4%-6.3pp	-9.1%-1.8pp	-7.3%+85.7pp	-93.0%+8.3pp	-101.4%+50.2pp	-151.6%	N/A
Current Ratio	9.33-23.8x	33.09+13.9x	19.19+11.6x	7.61-16.4x	23.98+2.9x	21.11-20.7x	41.83-24.6x	66.40+63.9x	2.52+0.4x	2.16-5.5x	7.69+7.7x	0.03
Debt-to-Equity	0.12+0.1x	0.030.0x	0.06-0.1x	0.16+0.1x	0.040.0x	0.050.0x	0.030.0x	0.02-0.6x	0.64-0.2x	0.810.0x	0.77	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-31.4%+0.2pp	-31.5%	N/A	-12.7%-4.5pp	-8.2%-2.8pp	-5.4%	N/A	-2.7%
Return on Assets	-24.5%+1.5pp	-26.0%	N/A	-12.3%-4.4pp	-7.9%-2.7pp	-5.3%	N/A	-2.7%
Current Ratio	4.72-1.0x	5.72-3.6x	9.33-19.0x	28.34+2.5x	25.86-18.4x	44.25+11.2x	33.09-3.4x	36.47
Debt-to-Equity	0.28+0.1x	0.21+0.1x	0.12+0.1x	0.040.0x	0.040.0x	0.020.0x	0.030.0x	0.03

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Immunovant Inc IMVT

$9.1B

Xenon Pharmaceut XENE

$6.0B

Crinetics Pharmaceuticals CRNX

$9.0B

Scholar Rock Holding SRRK

$7.2B

Soleno Therapeutics Inc SLNO

$2.8B

Where Viking Therapeutics Inc Ranks

Frequently Asked Questions

What is Viking Therapeutics Inc's annual revenue?

Viking Therapeutics Inc (VKTX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Viking Therapeutics Inc profitable?

No, Viking Therapeutics Inc (VKTX) reported a net income of -$359.6M in fiscal year 2025.

What is Viking Therapeutics Inc's return on equity (ROE)?

Viking Therapeutics Inc (VKTX) has a return on equity of -56.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Viking Therapeutics Inc's operating cash flow?

Viking Therapeutics Inc (VKTX) recorded an outflow of $278.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Viking Therapeutics Inc's total assets?

Viking Therapeutics Inc (VKTX) had $715.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Viking Therapeutics Inc spend on research and development?

Viking Therapeutics Inc (VKTX) invested $345.0M in research and development during fiscal year 2025.

How many shares does Viking Therapeutics Inc have outstanding?

Viking Therapeutics Inc (VKTX) had 116M shares outstanding as of fiscal year 2025.

What is Viking Therapeutics Inc's current ratio?

Viking Therapeutics Inc (VKTX) had a current ratio of 9.33 as of fiscal year 2025, which is generally considered healthy.

What is Viking Therapeutics Inc's debt-to-equity ratio?

Viking Therapeutics Inc (VKTX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Viking Therapeutics Inc's return on assets (ROA)?

Viking Therapeutics Inc (VKTX) had a return on assets of -50.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Viking Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Viking Therapeutics Inc (VKTX) held $705.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $278.7M over that year. Dividing the one by the other, the reported balance equals about 30 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Viking Therapeutics Inc's Altman Z-Score?

Viking Therapeutics Inc (VKTX) has an Altman Z-Score of 26.96, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Viking Therapeutics Inc's Piotroski F-Score?

Viking Therapeutics Inc (VKTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Viking Therapeutics Inc's earnings high quality?

Viking Therapeutics Inc (VKTX) reported a net loss of $359.6M while operations used $278.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.